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ABSTRACT 
A questionnaire was mailed to the third party providers (n=313) 
registered with the National Council for Prescription Drug Programs 
(NCPDP), State Medicaid Programs and Blue Cross plans not listed with 
the NCPDP. The response rate was 41.5%. The respondents were 
evaluated for their demographics (number of prescriptions processed, 
number of subscribers, number of drug benefit models and type of third 
party) and pre approval process (if they required the provider to obtain pre 
approval, process of pre approval, time required for giving pre approval 
and person responsible for obtaining the pre approval). Information was 
also gathered on drug utilization review conducted on compounded 
prescriptions and the reimbursement scheme for compounded 
prescriptions. 
The results of the study revealed that the majority of third party 
providers do not perform any kind of drug utilization review on their 
compounded prescriptions. Also most of the third party providers in the 
study group did not require their provider to obtain pre approval nor did 
they have a preapproved list of compounded prescriptions. Moreover 
most of the respondents reimburse for drugs compounded for FDA 
unapproved uses. 
It appears that there is a need for the third party to reevaluate their 
current reimbursement, review and coverage of compounded 
prescriptions. 
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INTRODUCTION 
Compounding is a pharmacist's prerogative and has always been a part of 
pharmacy practice. The laws of some states include compounding in their 
definition of the practice of pharmacyl. The Latin recipe Secundum artum meant 
that the pharmacist would use his professional knowledge to compound drugs 
into a dosage form. The pharmacist was well aware of the physical and chemical 
properties and could make the dosage form providing a therapeutic effect. 
Secundum arturn empowered the pharmacist to combine drugs into a 
medication. Even today with the latest technological advances and growth of the 
pharmaceutical industry, almost 98% of the pharmacists compound drugs 
though on a relatively smaller scale2. 
There are several reasons as to when and why a pharmacist may 
compound drugs. 
1. Pharmacists compound drugs when they are not commercially available 
in the required strength or dosage form as required for optimum patient 
therapeutic activity. Usually drugs are available only in strengths and dosage 
forms that provide ease of administration and optimum therapeutic effect to the 
majority of patients. Thus the provider may prescribe and the pharmacist 
prepare and dispense drugs needed in limited strengths or alternate dosage 
forms and/ or packaging. The problem becomes acute especially in geriatric and 
pediatric care. Many of the elderly have difficulty in swallowing and the 
provider often must tailor the dosage form to enhance patient compliance. In the 
case of pediatric medication many children are allergic to the dyes and 
preservatives found in commercially available products. Hence for this patients, 
the pharmacist can prepare the product free of such dyes or preservatives. 
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2. Many times, for reasons of stability, a product should be prepared just 
before it is dispensed. In such cases, the pharmacist compounds small quantities 
of the prescription when the need arises. 
3. Another form of compounding is in the field of radioactive substances. 
Nuclear pharmacists compound various radioactive substances for diagnosis, 
imaging and treatment of patients. 
4. Sometimes physicians and pharmacists work together to make a product 
that meets a specific patient need. At times this has led to the development of a 
new dosage form that later became commercially available. Some examples are 
fentanyl lozenges, minoxidil lotion and nystatin lozenges3. 
5. Home infusion therapy is the fastest growing segment of compounded 
prescriptions. The number of diagnoses that can be treated at home is increasing 
and so is the demand for home infusion therapy where compounding accounts 
for most of the product dispensed. The following table shows the market share 
of the various classes of drugs in home infusion market4. 
Infusion treatment category 
Antibiotic 
Total parenteral nutrition 
Enteral nutrition 
Chemotherapy 
Other 
Percent market share 
41 
23 
10 
7 
19 
Oncologists, gastroenterologists, internal medicine specialists, general 
practitioners, obstetricians/ gynecologists and pediatricians are the most 
common prescribers of home infusion therapy4. 
6. The emerging field of biotechnology is projected to provide tremendous 
opportunities for pharmacists to use their compounding skills. Many 
biotechnology drugs have a short half lifes, are expensive and require unique 
delivery systems. 
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However today this very heritage of compounding is in the midst of a 
controversy. In the past few years there have been several cases where 
pharmacists were clearly manufacturing under the guise of compounding. In 
one such case, the FDA attempted to regulate a pharmacy that was involved in 
the manufacture of more than 300,000 dosage units of albuterol sulfate and other 
inhalation therapy drugs per month for 6,000 patients, most of which were 
shipped by interstate commerces. Another firm was involved in the production 
of liquids in a 30 liter tank in a building that did not appear to be a pharmacy. 
This 'pharmacy location' had a shipping area, sterile area for compounding, 
mixing and filling area, a drug storage area, a billing area and two customer 
services offices. All the compounded products were shipped to customers by 
federal express or airborne express. There was absolutely no patient walk in 
with prescription dispensing service. The customers were pharmacies, medical 
supply firms and home health care facilities. This firm made its products by 
diluting brand name drugs and bulk drug products5. There were cases where 
the pharmacies diluted Proventil (a product of Schering laboratories), 
repackaged and marketed it as Proventil. Analysis of these samples found 
mislabeled or absent expiry dates and lot numbers, diluted concentrations of the 
antibacterial benzalkonium chloride and samples contaminated with 
pseudomonas5. 
It was not only these issues concerned with the large scale manufacturing 
operations that drew the attention of FDA but also some of the practices and 
issues surrounding the traditional compounding of products. There were cases 
where the patients were affected by the medication compounded by the 
pharmacist. One such example of injury to the patients resulting from 
compounded products occurred in 1990 in Pittsburgh, PA. Several patients 
suffered from eye infection from the indomethacin eye drops that had been 
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compounded by a pharmacist6. Two had to undergo surgical removal of the eye. 
In Nebraska some patients died after receiving microbially infected surgical 
solutions made by a hospital pharmacy6. 
All such instances were viewed by the FDA from a public health 
perspective. Until recently the number of such cases concerned with 
compounding that came to the FDA notice were few and relatively less 
significant8. Also the practice of pharmacy was mainly left to the domain of the 
state boards of pharmacy. However lately there has been an increase in the 
number of pharmacies involved in the large scale manufacturing of drugs 
providing large quantities of adulterated, misbranded or unapproved drugs. In 
other words these pharmacies were clearly violating the Food, Drug and 
Cosmetic acts. These pharmacies were operating as a pharmaceutical companies 
except unlike the latter they did not conform to FDA regulation. In view of 
public health and safety and efficacy of products, the FDA issued an FDA 
Compliance Policy Guide 7132.16 (CPG) in March 19929. The CPG discusses the 
factors that the agency will take into consideration while deciding whether a 
pharmacy has extended beyond the scope of traditional compounding and 
assumed the role of a manufacturer. According to these guidelines FDA action 
will take place in case the pharmacists resorted to the following activities. 
1. Soliciting business (e.g. promoting, advertising, or using sales persons) to 
compound specific drug products, product classes, or therapeutic classes 
of drug products. 
2. Compounding, regularly, or in inordinate amounts, drug products that 
are commercially available in the marketplace and that are essentially 
generic copies of commercially available, FDA approved products. 
3. Receiving, storing, or using drug substances without first obtaining 
written assurance from the supplier that each lot of the drug substance 
has been made in an FDA approved facility. 
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4. Receiving, storing or using drug components not guaranteed or otherwise 
determined to meet official compendia requirements. 
5. Using commercial scale manufacturing or testing equipment for 
compounding drug products. 
6. Compounding inordinate amounts of drugs in anticipation of receiving 
prescriptions in relation to the amounts of drugs compounded after 
receiving valid prescriptions. 
7. Offering compounded drug products at wholesale to other state licensed 
persons or commercial entities for resale. 
8. Distributing inordinate amounts of compounded products out of state. 
9. Failing to operate in conformance with applicable state law regulating the 
practice of pharmacy. 
The foregoing list of factors is not intended to be exhaustive and other 
factors may be appropriate for consideration in a particular case. CPG stated that 
FDA recognizes that pharmacists have traditionally compounded and 
manipulated reasonable quantities of drug upon receipt of a valid prescription 
(i.e., an oral or written order from a practitioner licensed by state law to 
administer or order the administration of the drug to an individual patient 
identified by the practitioner in the course of his or her professional practice) for 
an individually identified patient from a licensed practitioner. This traditional 
activity was not the subject of the CPG. According to the CPG, a pharmacist can 
compound in response to a valid prescription for an individual patient. Thus the 
CPG was only to differentiate between compounding and manufacturing. 
However the FDA officers at the local level sent warning letters to pharmacists 
for whom compounding constituted only around 2% of their total pharmacy 
sales7. These letters warned the pharmacists against FDA action in the event that 
they resorted to compounding. The reason was that any drug compounded in 
the pharmacy was a new drug and hence subject to NOA approval. This 
5 
( 
contradictory stand has created confusion among the pharmacists, pharmacist 
groups and other agencies as to whether compounding constitutes a violation of 
CPG. 
As part of its effort to clear the confusion prevailing over compounding 
vs. manufacturing, the American Pharmaceutical Association (APhA) in 
consultation with FDA and other pharmacists has defined compounding and 
manufacturing. 
Compounding has been defined as " the preparation, mixing, assembling, 
packaging or labeling of a drug or device (1) as the result of a practitioners 
prescription drug order or initiative based on the pharmacist /patient/ 
relationship in the course of professional practice or (2) for the purpose of, or as 
incident to research, teaching, or chemical analysis and not for sale or dispensing. 
Compounding also includes the preparation of drugs or devices in anticipation 
of prescription drug orders based on routine, regularly observed prescribing 
patterns4. 
Manufacturing on the other hand is defined as the production, 
preparation, propagation, conversion or processing of a drug or device either 
directly or indirectly by extraction from substances of natural origin or 
independent! y by means of chemical or biological synthesis and includes any 
packaging or repackaging of the substances or labeling or relabeling of its 
container and the promotion and marketing of such drugs or devices. 
Manufacturing also includes the preparation and promotion of commercially 
available products from bulk compounds for resale by pharmacies, practitioners 
or other person4. 
One of the largest groups of compounding pharmacists, Professional & 
Patients for Customized Care (P2C2) filed a lawsuit against the federal 
government and many of its agencies to block the enforcement of CPG on the 
6 
grounds that it violated the federal procedural law. The basic argument adopted 
by P2C2 was that the CPG, adopted by the FDA as an internal guideline is 
actually a substantial change in federal policy that significantly have an impact 
on pharmacy practitioners, and that the policy should have been promulgated as 
a formal rule with advance notice to the public to commentS. However the US. 
District court ruled out that the FDA could continue to take actions against the 
pharmacies based on CPG since CPG did not significantly impact the traditional 
compounding of pharmacy profession. P2C2 has filed an appeal with the Fifth 
Circuit Court of appeal that will be decided sometime this year since the 
submission of this thesis the compounding controversy still exists. 
All this confusion over compounding has raised questions regarding the 
third party coverage, review and reimbursement of compounded prescriptions. 
A detailed literature survey did not provide any information on the type of drug 
utilization review (DUR) performed on compounded prescriptions. In fact it is 
not even clear whether third party providers conduct DUR on compounded 
prescriptions. DUR can be performed on all the ingredients in the prescription or 
only on the active ingredient or the most costly ingredient. However the 
literature does not disclose any of this information. 
Second the literature does not discuss any issues pertaining to 
preapproval. It remains unclear whether third party organization have a 
formulary of drugs or formula that can be compounded. No information is 
available as to whether providers are required to obtain pre approval before 
compounding any prescription. Also it remains unknown as to who is 
responsible for obtaining preapproval (physician or pharmacist or either), the 
mechanics of the preapproval process (form, phones, faxes) and the time period 
needed to obtain pre approval. 
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Many times a physician in the course of his practice may prescribe a drug 
to be compounded for FDA unapproved uses. It is unclear as to whether these 
prescriptions will be reimbursed by the third party. Some or most of the 
compounded prescriptions may contain more than one active ingredient. As the 
number of active ingredients in the prescription increases the chances of adverse 
effects also increases. In the absence of any safety or efficacy studies, it remains 
unclear if the third party providers restrict the number of active ingredients per 
reimbursed compounded prescription. 
Third, the literature does not discuss the type of reimbursement scheme 
adopted by the third party for compounded prescriptions. Only five of the State 
Medicaid programs specifically refer to compounded products in their 
reimbursement scheme. The District of Columbia reimburses compounded 
prescriptions on the basis of either allowable charges of all billable ingredients 
plus dispensing fee or the providers usual charge to the publiclO. The Medicaid 
program in Mississippi reimburses compounded prescriptions for topical use 
only if at least one legend drug (in therapeutic amounts) is included in the 
ingredientslO. Mississippi also covers compounded oral medications when all 
ingredients are covered separately under their own drug codes in the formulary. 
The Medicaid program of Nebraska reimburses compounded prescriptions at the 
lesser value of product cost (Federal upper limit, State Maximum Allowable Cost 
or EACl) plus an appropriate dispensing fee or at the usual and customary 
charge to the publiclO. The Medicaid program of Pennsylvania has defined a 
compounded prescription as one that is prepared at the time of dispensing and 
involves the weighing of at least one ingredient that must be a legend drug in 
therapeutic amountlO. The Medicaid program of West Virginia defines 
1 EAC-Estimated Acquisition Cost is an estimation made by a third party, of the actual amount a pharmacy 
would pay a supplier for a given product. 
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compounded prescriptions as any legend medicament requiring a combination 
of any two or more substances to exclude normal reconstitution operationslO. 
There is no information regarding the reimbursement of compounded 
prescriptions under the remaining State Medicaid programs or by various 
private insurance companies. 
Finally no data is available on the growth or decline of compounded 
prescriptions over the years. Almost all pharmacists occasionally compound 
prescriptions but the contribution of these prescriptions to their total prescription 
sales either in terms of volume or dollar amount remains unclear. 
This study is designed to explore the issues of Drug Utilization Review, 
pre approval for compounding and the reimbursement scheme. The study 
focuses on the following areas: 
1. Current mode of reimbursement for compounded prescriptions 
This includes the formulas of the reimbursement scheme 
(e.g., EAC +dispensing fee), the number of models that reimburse 
compounded prescriptions and identify factors factors( e.g., dosage, time) 
affecting the reimbursement scheme. 
2. Problems with the current coverage schemes 
To include documenting whether drug utilization review is performed on 
compounded prescriptions and whether the insurer reimburses for FDA 
approved drugs compounded for unapproved uses. In addition the study 
gathered information as to whether the insurer requires their participating 
pharmacies to provide compounding services and the time frame within 
which the services have to be provided. 
9 
3. Limitations on compounded prescriptions coveraae 
To includes documenting the presence or absence of a formulary of drugs 
to be compounded, requirements for preapproval of compounding drugs, 
the type of preapproval process and the amount of time required for pre 
approval. 
10 
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METHODS 
MEASURES 
A draft questionnaire was initially developed. This consisted of 25 close 
ended questions pertaining to third party coverage, review and reimbursement of 
compounded prescriptions. The draft questionnaire was pretested, the panelist 
being graduate pharmacy students, faculty of the Division of Applied 
Pharmaceutical Sciences and third party administrators. The purpose for 
pretesting was to eliminate any discrepancies that might arise in the interpretation 
of these questions by the respondents. On the basis of the suggestions made by 
this group, a final questionnaire was developed. 
The questionnaire was mailed to the third party providers, throughout the 
United States who comprised the target population. The list of their names and 
addresses was obtained from the National Council for Prescription Drug 
Programs(NCPDP), the State Medicaid programs and the Blue cross plans not 
listed in the NCPDP. The study took into consideration Health Insurer 
(Government, Not for Profit and For Profit), Health Maintenance Organizations, 
Mail Service Prescription Company and Pharmacy Benefit Management 
Company. The target population therefore composed of 313 third party 
providers. 
The questionnaire (see appendix B ) was divided into four sections. The 
purpose of section one was to demographically describe the respondent. The 
respondents were asked to identify themselves as any of the following-for profit 
health insurance company, not for profit health insurance company, HMO, mail 
service prescription company, pharmacy benefit management company and 
Federal/State agency. Questions 2 and 3 sought to determine the number of 
subscribers enrolled and the total number of prescriptions processed during the 
11 
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calendar year 1993. Information was also gathered on the number of drug benefit 
models administered by the respondents under the capitation, fee for service and 
usual and customary reimbursement scheme. Hence section one attempts to 
describe the company in terms of the number of prescriptions processed, number 
of subscribers enrolled and the number of drug benefit models that in turn could 
be related to the reimbursement policy and coverage of compounded 
prescriptions. 
The purpose of section two is three fold. First information was gathered 
regarding the number of models that reimbursed compounded prescriptions. 
Those respondents who did not reimburse compounded prescriptions or 
reimbursed only under some of their models were asked whether they intended 
to reimburse under all their models within the next two years. Questions were 
directed towards gaining more information on the reimbursement formula (e.g. 
EAC +dispensing fee) and if these formulas differ according to the dosage form 
or the time required for compounding. 
Second the respondents were asked whether the company had any 
mechanism whereby they can identify when a drug is being compounded for 
FDA unapproved uses. Also an attempt was made to determine whether the 
respondents reimbursed FDA approved drugs compounded for unapproved 
uses. 
The final part of this section focused on the pre approval process. The 
respondents were asked whether they have a pre approved list of prescriptions to 
be compounded and whether they require the provider to obtain pre approval 
before compounding. When pre approval is required, a series of questions 
followed trying to gather more information with respect to the person responsible 
for obtaining the pre approval (prescriber or pharmacist), the pre approval 
12 
process (pre approval form, faxes, computer) and the number of hours required 
for pre approval. 
Section three dealt with drug utilization review (DUR). The focus was to 
determine whether the third party conduct DUR and the type of DUR 
(retrospective, prospective or concurrent). Moreover the respondents were asked 
whether they conduct DUR only on the single most costly ingredient in the 
formula or on all the ingredients. Those respondents who do not currently 
conduct DUR on compounded prescriptions were asked as to whether they 
intended conducting it within the next two years. 
The fourth and the final section of the questionnaire sought to determine 
the status of compounding under the present drug benefit programs. Questions 
were directed towards gaining details concerning the growth or decline of 
compounded prescriptions and the contribution of compounded prescriptions 
towards total prescription sales. Finally, the respondents were asked whether 
they require participating pharmacists to compound drugs and provide 
compounding services within a specified period of time. 
PROCEDURES 
A cover letter (Appendix Al) and self addressed, pre stamped envelope 
accompanied each questionnaire . The questionnaire was addressed to the person 
responsible for making corporate policies, usually the director of pharmacy 
programs. The cover letter explained in detail the intent of the study and 
requested the respondents to return the completed questionnaire within a 
specified period. To avoid bias and obtain accurate information the respondents 
were requested not to identify themselves. A month later, A second mailing with 
the same questionnaire and cover letter (Appendix A) was conductedand only 
those who had not replied were requested to return the questionnaire. 
13 
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Mailing of the questionnaire began on 12th December 1994. The 
deadline for the return was 15th January 1995. The follow up questionnaire was 
mailed on 23rd January and the deadline for the return was 20th February. 
DATA ANALYSIS 
The data was analyzed using SAS version 6.06 on the IBM Mainframe 
Computer System housed at the University of Rhode Island. The analysis was 
carried out to document the characteristics of reimbursement pertaining to 
compounded prescriptions using descriptive statistics. The main focus was on 
drug utilization review, pre approval, reimbursement scheme and the status of 
compounded prescriptions under the drug benefit program. 
The Proc Freq was used to determine the frequencies of the variables. On 
the basis of the frequencies, the pertinent variables were selected for bivariate 
analysis. The independent variables were dichotomised at thier mid point, e.g 
number of subscribers was dichotomised as more than 100,000 and 0-100,000. The 
independent variables included the type of third party, number of prescriptions 
processed, number of subscribers, number of drug benefit models and the 
percentage of compounded prescriptions in terms of total prescription volume. 
The dependent variables included the presence of DUR, number of ingredients on 
which DUR is conducted, factors (e.g. dosage, time) affecting the reimbursement 
formula, presence of a preapproved list of drugs to be compounded, whether the 
third party reimburses for FDA approved drugs compounded for unapproved 
uses, whether the third party require their provider to obtain pre approval before 
compounding prescriptions and the growth of compounded prescriptions (in 
terms of percentages) over the last two years. 
Chi-square statistic was performed to measure the degree of association. 
Three levels of association was used: highly significant with p-values less than 
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0.01, significant with p-values of 0.01-0.10 and marginally significant relationships 
had p-values of greater than 0.10 to 0.15. 
Prevalence odds ratio for the bivariate association between the 
independent variable and dependent variable was calculated using the formula 
(Kleinbaum 1982): 
Pr OR = (# of exposed cases)*(# of unexposed non cases) 
( # of exposed non cases)*(# of unexposed cases) 
A 95% Confidence Interval for the odds ratio was calculated using the following 
formula-
95% CI= Pr ORl±(l.96/X} 
where Pr OR is the prevalence odds ratio and Xis the square root of the chi 
square. 
Dichotomization of variables 
Independent variables 
1. 
2. 
3. 
4. 
Type of third party O=For profit health insurance company 
1-Not for profit health insurance company 
Number of prescriptons processed 
in the calendar year 1993 
Number of subscribers enrolled 
in the calendar year 1993 
Percentage of compounded prescriptions 
in terms of total prescription volume 
O=More than 500,000 
1 =0-500 ,000 
O=More than 100,000 
1=0-100,000 
O=Greater than 1 % 
1=0-1% 
Dependent variables 
1. Require the pharmacist to differentiate between 
compounded and non compounded prescriptions 
15 
O=Yes 
l=No 
( 2. Presence of a preapproved list of prescriptions O=Yes 
to be compounded l=No 
3. Able to identify when an FDA approved drug O=Yes 
is compounded for unapproved uses l=No 
4. Reimburse FDA approved drug compounded O=Yes 
for unapproved uses l=No 
5. Require the provider to obtain preapproval O=Yes 
before they can compound l=No 
6. Factors affecting the reimbursement of O=Dosage or time 
compounded prescriptions l=None 
7. Conduct drug utilization review O=Yes 
on compounded prescriptions l=No 
8. Allow more than one active ingredient O=Yes 
per compounded prescription l=No 
9. Growth of compounded prescriptions O=lncreased 
over the last two years l=Decreased 
10. Require all participating pharmacies O=Yes 
to compound prescriptions l=No 
11. Require the pharmacies to provide compounding O=Yes 
services within a reasonable period of time l=No 
16 
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RESULTS 
A total of 313 questionnaires (Appendix A) were mailed to the third party 
providers registered with the National Council for Prescription Drug Programs 
(NCPDP), the state Medicaid programs and the Blue Cross plans. A total of 142 
questionnaires were returned. Of these 6 were undeliverable. 5 were either not 
answered or incomplete. 1 was received after the cut off-date. Hence only 130 
questionnaires could be used for the final analysis (41.53%). 
A. CHARACTERISTICS OF THE THIRD PARTY COVERAGE, REVIEW 
AND REIMBURSEMENT OF COMPOUNDED PRESCRIPTIONS 
1. Demographics of third party providers 
Table 1 provides the summary of the demographics of third party 
providers. A total of 130 third party providers responded to the survey. 
Pharmacy Benefit Management Companies dominated the study group 
representing 31.0% of the study group followed by the Federal/State agencies 
that accounted for 27.1 %. 11.6% of the respondents were Health Maintenance 
Organizations while 4.7% constituted Mail Service Prescription Companies. For 
Profit Health Insurance Companies represented 19.4% of the study group and 
Not For Profit Health Insurance Companies the remaining 6.2%. 
About 63% of the third party providers processed more than 1,000,000 
prescriptions in the calendar year 1993. 16.5% of the respondents had 500,000-
1,000,000 prescriptions while 9.4% processed between 0-50,000 prescriptions 
during the same period. 50,000-100,000 and 100,000-500,000 prescriptions were 
processed by 3.1 % and 7.9% of the third party providers in the study group 
respectively. 
17 
37.5% of the third party providers had 100,000-500,000 subscribers 
enrolled in the calendar year 1993. More than 1,000,000 subscribers were 
enrolled by 22.7% of the respondents. Around 10,000-50,000 and 50,000-100,000 
subscribers were enrolled by 5.5% and 11.7% of the third party providers in the 
study group respectively. 1.6% of the respondents had 0-5,000 and another 1.6% 
had 5,000-10,000 subscribers enrolled in the calendar year 1993. The remaining 
19.5% of the third party providers in the study group had 500,000-1,000,000 
subscribers. 
Majority of the respondents(72.2%) had no models under the capitation 
system. 4.8% of the third party providers had one, 8.7% had two and 0.8% had 
three drug benefit models. 2.4% and 11.l % of the respondents revealed that they 
had four and more than four models respectively under the capitation system. 
14.3% of the respondents had no drug benefit plans under the fee for 
service system. One, two and three drug benefit models were available under 
this system in the case of 23.0%, 7.9% and 3.2% of the third party providers in the 
study group respectively. 4.0% of the respondents have four models and the 
remaining 47.6% had more than four models under the fee for service 
reimbursement scheme. 
Under the usual and customary system, 46.8% had no drug benefit 
models. 13.5% had one, 9.5% had two, 1.6% had three and yet another 1.6% of 
the respondents revealed that they four models under the usual and customary 
reimbursement scheme. 
18 
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Table 1. Demographic characteristics of third party 
Characteristics 
Type of third party 
For profit health insurance company 
Not for profit health insurance company 
Health Maintenance Organization 
Mail Service Prescription Company 
Pharmacy Benefit Management Company 
Federal/State agency 
Number of prescriptions processed in 1993 
0-50,000 
50 ,000-100 ,000 
100 ,000-500 ,000 
500 ,000-1,000 ,000 
More than 1,000,000 
Number of subscribers enrolled in 1993 
0-5,000 
5 ,000-10 ,000 
10 ,000-50 ,000 
50 ,000-100 ,000 
100 ,000-500 ,000 
500 ,000-1,000 ,000 
More than 1,000,000 
Number of Drug Benefit Models 
Capitation 
None 
One 
Two 
Three 
Four 
More than four 
19 
% Total 
(n=130) 
6.2 
19.4 
11.6 
4.7 
31.0 
27.l 
9.4 
3.1 
7.9 
16.5 
63 
1.6 
1.6 
5.5 
11.7 
37.5 
19.5 
22.7 
72.2 
4.8 
8.7 
0.8 
2.4 
11.l 
Table 1.. .. continued 
( 
Characteristics %Total 
(n=130) 
Fee for service 
None 14.3 
One 23.0 
Two 7.9 
Three 3.2 
Four 4.0 
More than four 47.6 
Usual and customary 
None 46.8 
One 13.5 
Two 9.5 
Three 1.6 
Four 1.6 
More than four 27.0 
20 
( 
2. PROCESS OF PREAPPROVAL 
A summary of the results of the pre approval process is presented in Table 2. Of 
the 130 respondents, 10.8% had a preapproved list of prescriptions to be 
compounded, however the majority (89.2%) stated that they did not have a 
preapproved list. 
82.2% of the third parties in the study group did not require the provider 
to obtain pre approval before they could compound and receive reimbursement. 
17.8% required the providers to obtain pre approval. Of those that required pre 
approval, 21.7% placed the responsibility on the prescriber while 47.8% required 
the pharmacist to obtain pre approval. 30.4% of the third party providers 
in the study group stated that they needed either the pharmacist or the prescriber 
to obtain the pre approval. 
The process of pre approval also varied among the respondents who have 
the requirement of pre approval. 30.4% required the use of phone for obtaining 
pre approval. Pre approval form and computer were used by 8.7% and 4.3% of 
the respondents respectively. 8.7% did not restrict the process of pre approval. 
The providers could choose any of the processes. 4.3% each of the third parties 
required the provider to choose between form and fax or phone and fax or 
computer and phone or phone, fax and computer. 
43.5% of the respondents revealed that they gave approval immediately. 
About 34.8% stated that the process usually takes less than 24 hours while 21.7% 
replied that it took about 48 hours. 
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Table 2 Summary of the process of pre approval 
Pre approval 
Presence of a preapproved list of prescriptions 
to be compounded 
Yes 
No 
Require the provider to obtain pre approyal 
before compounding the prescription 
Yes 
No 
Person responsible for obtaining pre approval 
Prescriber 
Pharmacist 
Either pharmacist or prescriber 
Process of pre approval 
Form 
computer 
Phone 
Any 
Form or fax 
Phone or fax 
Phone or computer 
Phone or fax or computer 
Form or computer or phone 
Form or phone or fax 
Number of hours to obtain pre approval 
Immediate! y 
Within 24 hours 
Within 48 hours 
More than 48 hours 
22 
% Total 
(n=130) 
10.8 
89.2 
17.8 
82.2 
21.7 
47.8 
30.4 
8.7 
4.3 
30.4 
8.7 
4.3 
4.3 
4.3 
4.3 
13.0 
17.4 
43.5 
34.8 
21.7 
0.00 
( 
3. DRUG UTILIZATION REVIEW 
Table 3 shows the results of the Drug Utilization Review. 57.4% of the third 
party providers in the study group currently conduct drug utilization review on 
compounded prescriptions while the remaining 42.6% do not. Of those who do 
not perform DUR about 25% planned to do it in the next year, 8.9% in the next 
two years and 3.6% after two years. 57.1 % of the third party who do not conduct 
DUR has no intention of conducting it even in future while 5.4% are still 
undecided as to whether they should perform DUR on compounded 
prescriptions. 
30.1 % conduct retrospectively followed by 26.0% who conduct either of 
the three types. Concurrent review is performed by 9.6% and prospective by 
5.5% of the respondents. About 8.2% of the respondents revealed that they 
conduct either prospective or retrospective studies while 1.4% stated that they 
perform either prospective or concurrent DUR. 
52.1 % of the third party providers in the study group stated that they 
conduct DUR on all the ingredients in the prescription. However 41.1 % of the 
respondents revealed that only the single costly ingredient in the prescription is 
taken into consideration for performing DUR. The remaining 6.8% of the 
respondents conduct DUR on either the costly ingredient or on all the 
ingredients. 
With reference to the number of active ingredients in the compounded 
prescriptions about 94.5% did not place any restrictions on the number of active 
ingredients to be included in the compounded prescriptions. However 5.5% of 
the respondents did not allow the provider to compound more than one active 
ingredient per prescription. 
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Table 3 Process of Drug Utilization Review 
Drug Utilization Review 
Conduct Drug Utilization Review on 
compounded prescriptions 
Yes 
No 
Intend to conduct DUR on compounded 
prescriptions in future 
Yes, within one year 
Yes, within two years 
Yes, after two years 
No 
Don't.know 
Type of Drug Utilization Review 
Prospective 
Concurrent 
Retrospective 
Concurrent & Retrospective 
Prospective & Retrospective 
Prospective & Concurrent 
All three types 
Number of ingredients on which 
DUR is performed 
Only on the single costly ingredient 
On all the ingredients 
Either on costly or on all the ingredients 
Allow more than one active ingredient 
per compounded prescription 
Yes 
No 
24 
% Total 
(n=130) 
57.4 
42.6 
25.0 
8.9 
3.6 
57.l 
5.4 
5.5 
9.6 
30.1 
19.2 
8.2 
1.4 
26.0 
41.1 
52.1 
6.8 
94.5 
5.5 
( 
Status of compounded prescriptions 
The status of compounded prescriptions under the drug benefit models is 
presented in table 4. 46.9% of the respondents were not aware if there was an 
increase or decrease in compounded prescriptions. 16.9% felt that it had 
remained the same. An increase of 0-5% was reported by 14.6% and 7.69% of the 
respondents stated that compounded prescriptions had increased by 6-10%. 
Another 3.85% of the respondents was of the opinion that compounded 
prescriptions may have increased by 11-15% while an increase of 16-20% was felt 
by 1.54% of the respondents. 
Of the third party providers who reported a decline in compounded 
prescriptions, 4.61 % stated that there was a decline of 6-10% while a decline of 0-
5% was reported by 0.77% of the third party providers in the study group. 1.54% 
of the respondents revealed a decline of 16-20%. 
About 66.4 % reported that compounded prescriptions accounted for less 
than 1 % of their total prescription volume. 24% of the respondents revealed that 
it made up 1-5% of their total prescription volume. Compounded prescriptions 
represented about 6-10% of the prescription volume in 1.6% of the respondents 
drug benefit programs. 8% of the third party providers in the study were not 
aware of the contribution of compounded prescriptions to their total prescription 
volume. 
34.6% of the respondents required their participating pharmacies to 
compound prescriptions under all their drug benefit models while 1.5% required 
it only under some models. 63.8% did not place any emphasis on providing 
compounding services by their pharmacies. 
21.5% of the third party providers in the study allowed a time limit on 24 
hours to their pharmacies for providing compounding services. A time period of 
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more than 24 hours was acceptable to 3.8% of the respondents. 74.6% of the third 
party providers in the study group revealed that they did not place any time 
restrictions on their pharmacies for providing compounding services. 
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( Table 4 Status of compounded prescriptions 
Variable 
Percentage of compounded prescriptions 
in terms of total prescription volume 
Less than 1% 
1-5% 
6-10% 
Don't know 
Growth in compounded prescriptions 
Increased by 0-5% 
Increased by 6-10% 
Increased by 11-15% 
Increased by 16-20% 
Increased but don't 
know by how much 
Decreased by 0-5% 
Decreased by 6-10% 
Decreased by 16-20% 
Remained the same 
Don't know 
Require all participating pharmacies 
to provide compounding services 
Yes, in all the models 
Yes, in some of the models 
No 
Require the pharmacies to provide services 
within a reasonable period of time 
Yes, within 24 hours 
Yes, more than 24 hours 
No 
27 
% Total 
(n=130) 
66.4 
24.0 
1.6 
8.0 
14.62 
7.69 
3.85 
1.54 
1.54 
0.77 
4.61 
1.54 
16.92 
46.92 
34.6 
1.5 
63.8 
21.5 
3.8 
74.6 
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Reimbursement scheme 
A summary of the reimbursement scheme is given in table 5. 
All the third party providers in the study reimbursed compounded prescriptions 
under their capitation scheme. 88% of them reimbursed under all the models 
while 11.43% reimbursed under some of the models. Of the respondents who 
offered fee for service scheme, 94.39% reimbursed compounded prescriptions 
under all the models while 4.67% reimbursed under some of their models. The 
remaining 0.93% did not reimburse compounded prescriptions under any of 
their fee for service models. Regarding the third party providers who had the 
usual and customary models, 86.57% reimbursed under all their models while 
7.46% reimbursed only under some of their models. 6.89% of the respondents 
did not reimburse under any of their usual and customary models. 
The majority of the respondents 82.2% required their provider to 
differentiate between compounded and non compounded prescriptions for 
reimbursement. The remaining 17.8% of the third party providers in the study 
revealed that they did not require the pharmacist to specify the type of 
prescription. 
31.5% of the respondents stated that they were not able to identify when 
an FDA approved drug is compounded for unapproved uses. 68.5% of the third 
party providers could determine when an FDA approved drug was 
compounded for unapproved uses. 
Regarding the reimbursement for FDA unapproved uses, 50.4% of the 
respondents stated that they reimburse an FDA approved drug compounded for 
unapproved uses. 49.6% revealed that they did not reimburse for the same. 
Dosage of the compounded prescription was taken into consideration for 
reimbursement by 4.0% of the respondents. 8.0% of the third party in the study 
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group took time required for compounding into account while 10.4% took both 
time and dosage into account while reimbursing compounded prescriptions. 
77.6% of the third party providers revealed that none of these factors affected 
their reimbursement formula. 
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Table 5 Summary of the reimbursement scheme 
Reimbursement scheme 
Number of models that reimburse 
compounded prescriptions 
Capitation 
All 
Some 
None 
Fee for service 
All 
Some 
None 
Usual and customary 
All 
Some 
None 
Require the provider to differentiate between 
compounded and non compounded prescriptions 
Yes 
No 
Able to identify when an FDA approved drug 
is compounded for unapproved uses 
Yes 
No 
Reimburse FDA approved drugs compounded 
for unapproved uses 
Yes 
No 
Factors affecting the reimbursement scheme 
Dosage 
Time required for compounding 
Both dosage and time 
None 
30 
% Total 
(n=130) 
88.0 
11.43 
0.00 
94.39 
4.67 
0.93 
86.57 
7.46 
6.89 
82.2 
17.8 
31.5 
68.5 
50.4 
49.6 
4.0 
8.0 
5.6 
82.4 
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The Bivariate Relationship Between the Independent Variables and If the 
Third Party Require the Provider to Differentiate Between Compounded and 
Non Compounded Prescriptions for Reimbursement 
The analysis for the relationship between the third party requirement to 
differentiate between compounded and non compounded prescriptions and the 
independent variables are shown in table 6. No statistically significant 
association was found among any of the variables. The chi-square value ranged 
from 0.002 (number of drug benefit models) to 1.411 (type of third party). 
Table 6 Summary of the bivariate association of the independent 
variables and if the third party requires their providers to 
differentiate between compounded and non compounded 
prescriptions for reimbursement. 
Variable 
Type of third party 
(For profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs. <100,000) 
Number of drug benefit models 
(>8 vs. <8) 
Percentage of compounded prescriptions 
in terms of total prescription dollars 
(~1 vs. <1) 
31 
p-value 
1.411 0.235 
0.179 0.672 
0.074 0.785 
0.002 0.965 
0.405 0.525 
( Bivariate Association Between The Independent Variables and if the Third Party have a Preapproyed List of Prescriptions to be Compounded 
The analysis for the bivariate association for the presence of a 
preapproved list of prescriptions to be compounded is presented in table 7 . The 
variable , number of drug benefit models and type of third party were the only 
statistically significant variables. The prevalence odds ratio for this variables 
were 3.17 and 0.35 respectively. One of the variables, percentage of 
compounded prescriptions had cells too small to count, i.e., there was only one 
respondent in a particular cell. The remaining variables had Chi-squares 0.629 
(number of prescriptions) and 0.068 (number of subscribers) 
Table 7 Summary of the bivariate association of the independent 
variables and presence of a preapproved list of prescriptions to 
be compounded 
Variable x2 
Type of third party 3.317 
(For Profit vs. Not For Profit) 
Number of prescriptions 0.629 
(>500,000 vs. <500,000) 
Number of subscribers 0.068 
(>100,000 vs. <100,000) 
Number of drug benefit models 4.100 
(>8 vs. <8) 
Percentage of compounded prescriptions 
in terms of total prescription dollars 
(~1 vs. <1) 
32 
p-value Pr OR 95%CI 
0.069 0.35 
0.428 
0.795 
0.043 3.17 1.037,9.68 
CELLS TOO SMALL TO COUNT 
( 
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The Bivariate Relationship Between the Independent Variables and if the 
Third Party can Identify when an FDA Approved Drug is Compounded for 
Unapproved Uses 
The variables, number of prescriptions and number of subscribers did not 
reveal any statistically significant association with Chi-square values of 0.011 and 
1.007 respectively. The variables, number of drug benefit models (X2=2.273, 
p=0.132) and the type of third party (X2=2.294, p=0.13) showed a significant 
association with prevalence odds ratio of 1.78 and 0.56 respectively. (Table 8) 
Table 8 Summary of the bivariate association between the independent 
variables and if the third party can identify when an FDA 
approved drug is compounded for unapproved uses 
Variable 
Type of third party 
(For Profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs.< 100,000) 
Number of drug benefit models 
(>8 vs. <8) 
% of compounded prescriptions in 
terms of total prescription dollars 
(~1 vs. <1) 
2.294 
0.011 
1.007 
2.273 
0.192 
33 
p-yalue PrOR 95%CI 
0.130 0.56 0.265,1.183 
0.916 
0.316 
0.132 1.78 0.843, 3.766 
0.662 
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The Bivariate Association Between the Independent Variables and if the Third 
Party Reimburse for FDA Approved Drug Compounded for Unapproved Uses. 
The analysis for the bivariate association between the independent 
variables and reimbursement for FDA approved drug compounded for 
unapproved uses as the dependent variable is presented in Table 9 . None of 
the variables showed any statistically significant association. The Chi-square 
value ranged from 0.034 (number of prescriptions) to 1.716 (percentage of 
compounded prescriptions). 
Table 9 Summary of the bivariate association between the independent 
variables and if the third party reimburse for FDA approved 
drugs compounded for unapproved uses 
Variable 
Type of third party 
(For Profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs. <100,000) 
Number of drug benefit models 
(>8 vs. <8) 
Percentage of compounded prescriptions 
in terms of total prescription dollars 
(~1 vs. <1) 
34 
p-value 
0.626 0.429 
0.034 0.854 
1.556 0.212 
0.949 0.330 
1.716 0.190 
( 
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The Bivariate Association Between the Independent Variables and if the Third 
Party Require the Provider to obtain Pre approval before they can compound 
and receive reimbursement 
The analysis for the association between whether the third party require their 
providers to obtain pre approval before they can compound and receive 
reimbursement and the independent variables is found in Table 10 . The 
variables, number of prescriptions processed in the calendar year 1993 (X2=4.S39, 
p=0.033) number of subscribers enrolled during the same period (X2=2.087, 
p=0.149) and the type of third party (X2=2.374, p=0.098) showed statistically 
significant association. The prevalence odds ratio associated with these variables 
were 0.342, 0.473 and 0.466 respectively. 
The summary of the analysis is presented in table 10. 
Table 10 Summary of the bivariate association between independent 
variables and if the third party require the provider to obtain 
pre approval 
Variable x2 p-value Pr OR 95%CI 
Type of third party 2.734 0.098 0.466 0.188,1.15 
(For Profit vs. Not For Profit) 
Number of prescriptions 4.539 0.033 0.342 0.12,0.918 
(>500,000 vs. <500,000) 
Number of subscribers 2.087 0.149 0.473 0.17,1.305 
(>100,000 vs. <100,000) 
Number of drug benefit models 0.261 0.610 
(>8 vs. <8) 
% of compounded prescriptions in 1.620 0.203 
terms of total prescription dollars 
(Ll vs. <1) 
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The Bivariate Association Between the Independent Variables and if the 
Reimbursement Scheme differ based On Dosage. Time Required For 
Compounding or other factors. 
The analysis for the relationship between the factors affecting the 
reimbursement formula and the independent variables is presented in table 11. 
The analysis did not reveal any statistically significant variables. The Chi-square 
value was 1.895 for the variable, number of prescriptions, 1.32 for the number of 
subscribers and 0.188 for the number of drug benefit models. The variable 
percentage of compounded prescriptions had cells too small to count. 
Table 11 Summary of the bivariate association between independent 
variables and factors affecting the reimbursement scheme 
Variable 
Type of third party 
(For Profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs. <100,000) 
Number of drug benefit models 
(>8 vs. <8) 
Percentage of compounded prescriptions 
in terms of total prescription dollars 
(~1 vs. <1) 
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p-yalue 
0.083 0.773 
1.895 0.169 
1.32 0.251 
0.188 0.665 
CELLS TOO SMALL TO COUNT 
I 
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The Bivariate Association Between the Independent variables and if the Third 
Party Conduct Drug Utilization Review on Compounded Prescriptions 
The analysis for the bivariate association between the presence/ absence of 
DUR and the independent variables revealed statistically significant association 
between the type of third party (X2=4.070, p=0.044) and the dependent variable. 
The Chi-square value for the variables ranged from 0.076 (percentage of 
compounded prescriptions) to 1.939 (number of prescriptions). The summary of 
the analysis is shown in table 12. 
Table 12 Summary of the bivariate association between the independent 
variables and if the third party conduct Drug Utilization Review 
Variables x2 p-value Pr OR 95%CI 
Type of third party 4.070 0.044 0.4722 0.97,2.27 
(For Profit vs. Not For Profit) 
Number of prescriptions 1.939 0.164 
(>500,000 vs. <500,000) 
Number of subscribers 0.261 0.610 
(>100,000 vs. <100,000) 
Number of drug benefit models 0.712 0.399 
(>8 vs. <8) 
Percentage of compounded prescriptions 0.076 0.782 
in terms of total prescription dollars 
(2::.1 % vs. <1 %) 
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The Bivariate Association Between the Independent Variables and if the Third 
Party Allow More than one Active Ingredient Per Compounded Prescription 
The analysis for the association between the number of ingredients per 
compounded prescription as the dependent variable and the independent 
variables is given in table 13. No statistically significant association was found 
for the variables number of prescriptions (X2=0.189) and the number of 
subscribers (X2=0.181). The variable type of third party had an odds ratio of 3.8. 
The variable number of drug benefit models also showed significant association 
with Chi-square as 3.417 and a p-value of 0.065. The prevalence odds ratio for 
this variable was 0.228. The variable percentage of compounded prescriptions 
had cells too small to count. 
Table 13 Summary of the bivariate association between the independent 
variables and if the third party allow more than one active 
ingredient per compounded prescription 
variables 
Type of third party 
(For Profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs. <100,000) 
Number of drug benefit models 
(>8 vs. <8) 
% of compounded prescriptions in 
terms of total prescription dollars 
(2:1 vs. <1) 
p-yalue Pr OR 95%CI 
2.73 0.099 3.8 0.78,18.5 
0.189 0.663 
0.181 0.671 
3.417 0.065 0.228 0.047,1.09 
CELLS TOO SMALL TO COUNT 
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The Bivariate Association Between the Independent variables and the Third 
Party Perception about the Growth of Compounded Prescriptions Over the 
Last Two Years 
The analysis revealed statistically significant relationship between the 
dependent variable and the number of drug benefit models (X2=5.745, p-
value=0.017). The prevalence odds ratio was 2.553. The other three variables 
had Chi-square values ranging from 0.007(type of third party) 4.076 (number of 
prescriptions). 
Table 14 Summary of the bivariate association between the independent 
variables and their knowledge about the growth of compounded 
prescriptions over the last two years 
variable 
Type of third party 
(For Profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs. <100,000) 
Number of drug benefit models 
(>8 vs. <8) 
0.007 
4.076 
1.438 
5.745 
p-yalue Pr OR 95% CI 
0.933 
0.043 
0.23 
0.017 2.553 1.185,5.495 
% of compounded prescriptions in 0.359 0.549 
terms of prescription dollars 
(~1 vs. <1 
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The Bivariate Association Between the Independent Variables and if the Third 
Party Require their Participating Pharmacies to Provide Compounding 
Services. 
The analysis for the relationship between the requirement for the 
pharmacies to provide compounding services and the independent variables is 
presented in table 15. The analysis revealed significant association for the 
variable type of third party (X=4.085, p=0.043) with prevalence odds ratio of 
0.472. The Chi-square values for the other independent variables ranged from 
0.062 (number of subscribers) to 1.164 (number of prescriptions). 
Table 15 Summary of bivariate association between the independent 
variables and if the third party require their participating 
pharmacies to provide compounding services. 
variable 
Type of third party 
(For Profit vs. Not For Profit) 
Number of prescriptions 
(>500,000 vs. <500,000) 
Number of subscribers 
(>100,000 vs. <100,000) 
Number of drug benefit models 
(>8 vs. <8) 
% of compounded prescriptions in 
terms of total prescription dollars 
(~1 vs. <1) 
x2 p-value Pr OR 95% CI 
4.085 0.043 0.472 0.228,0.977 
1.164 0.281 
0.062 0.804 
0.338 0.561 
1.162 0.281 
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The Bivariate Association Between the Independent Variables and if the Third 
Party Require their Pharmacists to Provide Compounding Services Within a 
Specified Period. 
The analysis did not showany significant association with the dependent 
variable. The Chi-square values were 1.256 (number of subscribers), 0.726 
(number of subscribers), 1.576 (number of drug benefit models) and 1.233 for the 
type of third party. The variable percentage of compounded prescriptions had 
cells too small to count i.e., one of the cells had one respondent. The summary of 
the analysis is shown in Table 16. 
Table 16 Summary of bivariate association between the independent 
variables and if the third party require their pharmacists to 
provide compounding services within a specified time period 
variables x2 p-yalue 
Type of third party 1.233 0.267 
(For Profit vs. Not For Profit) 
Number of prescriptions 0.246 0.620 
(>500,000 vs. <500,000) 
Number of subscribers 0.268 0.605 
(>100,000 vs. <100,000) 
Number of drug benefit models 1.576 0.209 
(>8 vs. <8) 
% of compounded prescriptions in CELLS TOO SMALL TO COUNT 
terms of total prescription dollars 
(Ll vs. <1) 
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DISCUSSION 
Table 1 showing the demographic characteristics reveal that the majority 
(72.7%) of third parties do not have any models under the capitation system. 
There seems to be a general favor for fee for service and the usual and customary 
models. In the capitation models the pharmacy receives a set dollar amount per 
person per time period for providing the needed services to that person for that 
time period. However the pharmacy has to assume some finanacial risk inherent 
in the capitation system and hence the pharmacies often resists the capitation 
models. The third party should have sufficient market strength and market 
penetration if they want to increase their capitation models. The fee for service 
models on the other hand are better understood and accepted by both the third 
party and the pharmacy. Hence there may be less models under the capitated 
system and a general favor for the fee for service or usual and customary models. 
89.2% of the respondents in this study do not have a preapproved list. 
(Table 2). 82.2% do not require providers to obtain pre approval. Only 4.65% of 
the third parties in the study group had both a preapproved list and required 
providers to obtain pre approval before compounding. 75.97% did not have a 
preapproved list and did not require providers to obtain pre approval. The 
remaining respondents either had a preapproved list or required pre approval but 
not both. These results are important because no safety or efficacy studies have 
been conducted on the compounded prescriptions. The prescribers during their 
course of medical practice may write a prescription that they feel might provide 
optimum therapeutic effect for the patient. Also the pharmacists based on 
stability, drug interactions and therapeutic effect of drugs will compound the 
prescriptions. It is possible that there may be errors while calculating the quantity 
of drug needed, the uses for which it is to be compounded and the interaction 
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among the ingredients in the formula. The results of this study show that without 
any pre approval requirement or any pre approval process as is the case with the 
majority of the third party (75.97%) there may be no check on what and why the 
prescription is being compounded. There are no studies that deal specifically 
with the errors (e.g miscalculation of ingredients, weighing out the wrong 
quantity of active ingredient) made while compounding prescriptions. In the 
absence of these studies it is difficult to determine the magnitude of the 
seriousness of a situation where there is no preapproved list or any pre approval 
requirement. However based on studies that deal with errors (mislabeling, wrong 
dose) made by the pharmacist while dispensing non compounded prescriptions 
(Guernsey B.G &et al) one might say that there is a distinct likelihood that some or 
many kinds of errors in compounding prescriptions might be taking place . This 
is important from the standpoint of saving dollars by not only paying for 
unnecessarily compounded prescriptions but also from the perspective of safety 
of the patient. This raises the issue of both quality of care and cost benefit. 
The processes of pre approval also vary greatly among the respondents as 
can be seen from the results shown in Table 2. Majority of them use the phone for 
the pre approval. A proportion of the third party providers still uses a pre 
approval form. This raises the question of the number of hours it takes to obtain 
the pre approval and consequently the number of hours the patient has to wait 
before receiving the medication. Only 43.5% of the third party give approval 
immediately. 34.8% and 21.7% of the respondents require 24 and 48 hours 
respectively to give pre approval. In this case the patient has to wait for a day or 
two or more than that before receiving their medication. This issue may be 
serious in some life threatening cases where medication is needed immediately. 
About 42.6% of the respondents do not conduct any drug utilization 
review on compounded prescriptions (Table 3). Among these, 57.1% have no 
43 
( 
intention of conducting it in future and 5.4% are still undecided. Thus it can be 
said that approximately half of the third party providers in the study group do 
not currently conduct drug utilization review. When this percentage is combined 
with the percentage of third party providers that do not have a preapproved list 
(89.2%) and do not require pre approval (82.2%) for compounding, it assumes 
more importance. When a provider seeks pre approval for a compounded 
prescription, the insurance company usually checks for the drug, dose and if the 
drug is included in the formulary if one exists. Drug Utilization Review allows 
the insurance company to focus on providers who are overprescribing, identify 
problems with the quality of care, a potential drug abuse problem or problems 
with compliance with medical treatment on the part of the members. The tighter 
the pre approval process, the greater the insurance plans ability to manage 
utilization. An approval process by itself will not automatically control utilzation 
although it will have an effect. 
Of those respondents who conduct a review about 30.1 % conduct 
retrospective review (i.e. after the prescription has been compounded). Only 9.6% 
conduct concurrent review(i.e. when the prescription is compounded). Also of 
those who conduct review 41.1 % conduct only on the single costly ingredient. 
This may or may not be the active ingredient in the prescriptions. Also if this is 
the active ingredient there may be more active ingredients on which the review is 
not performed since 94.5% of the third party allow more than one active 
ingredient to be included per compounded prescription. 
As the number of active ingredients in the prescription increases the 
chances of adverse effects for the patients may also increase. Besides almost all of 
them perform DUR only on one ingredient. Thus when you combine the number 
of ingredients allowed in the prescription and the number of ingredients on 
which DUR is performed the magnitude of the seriousness of the situation 
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increases. For example in the case of compounded progesterone suppositories it 
makes no difference on the number of ingredients on which DUR is performed 
since it contains only one active ingredient progesterone. However in the case of 
a compounded prescription containing benadryl and nystatin it makes a 
difference as to number of ingredients on which DUR is performed. 
Third party providers usually clssify prescriptions either by therapeutic 
class or by individual drugs for conducting DUR. Since compounded 
prescriptions forms a small portion either as a class or as drugs they are spread 
over the entire category. Under this situation (if at all) the third party conduct 
retrospective DUR they cannot avoid the errors that has already been made while 
compounding the prescription because the review is conducted only after the 
prescription has been prepared and dispensed. Thus the very purpose for which 
DUR is conducted viz. patient safety and cutting down unnecessary costs is not 
served. 
Almost all the models reimburse compounded prescriptions (Table 5). 
However 68.5% of the third party cannot identify when a drug is compounded for 
unapproved uses. It is quite likely that a number of these prescriptions might be 
compounded for some uses for which an FDA approval has not been obtained. 
Besides 50.4% of the third party reimburse FDA approved drugs compounded for 
unapproved uses. This does not check the compounding of drugs for 
unapproved uses. 
Results of the study show that the third parties do not consider dosage 
form or the time required for compounding into consideration while reimbursing 
the pharmacists (Table 5). A pharmacist who compound suppositories (consume 
more time and is difficult to prepare) may be paid the same as a pharmacist who 
compounds solutions. This may lead to some pharmacies deciding not to 
compound prescriptions or to compound only selective prescriptions. 
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Only 16.2% of the respondents felt that the number of compounded 
prescriptions have remained the same (Table 5). 46.92% were not even aware of 
the growth of compounded prescriptions. Almost 25% of the respondents felt 
that there was an increase in compounded prescriptions. About 5% felt that there 
was a decrease. The difference in response maybe due to the fact that 
compounded prescriptions constitutes only a small proportion of the total 
prescription volume and as such is considered to play a negligible part in the 
drug benefit programs. This can be concluded from the results of the percentage 
of compounded prescriptions in terms of total prescription dollars. A majority of 
the third party providers (66.4%) stated that compounded prescriptions only 
made up less than 1 % of their prescription dollars. 24% said that it made up 1-5% 
of their prescription dollars. When the figure of about two billion prescriptions 
dispensed per year in community pharmacies converted to its dollar value it 
assumes more importance. 
The results of the bivariate analysis revealed that the variable, number of 
drug benefit models is associated with some of the dependent variables. There 
seems to be a positive association between the number of drug benefit models and 
the presence of preapproved list. The prevalence odds ratio of 3.17 indicates that 
third party with drug benefit models greater than eight are three times more 
likely to have a preapproved list than those with relatively less number of models. 
Those with higher number of models (>8) are also 1.78 times more likely to 
identify when an FDA approved drug is compounded for unapproved FDA uses. 
However it is important to note that the confidence interval includes one which 
indicates that there may or may not be an association. Besides there seems to be 
an association between the number of drug benefit models and if the third parties 
allow more than one ingredient per compounded prescription. Third parties with 
more drug benefit models are only one fifth times more likely to allow more than 
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confidence interval makes it difficult to draw any definite conclusion regarding 
the association. The third party providers with more drug benefit models are also 
2.553 times more likely to be aware of the growth of compounded prescriptions 
compared to those with relatively less number of models. The reason for this 
maybe that as the number of drug benefit models increases there is a high 
likelihood that these plans have better management. The presence of 
sophisticated controls also increase as the number of plans increases. 
There results of the study also revealed an association between the 
variables, number of prescriptions processed, number of subscribers enrolled 
and the requirement for preapproval. Third party with prescriptions greater than 
500,000 are one third times likely to require preapproval and those with more 
than 100,000 subscribers are one half times more likely to have the requirement 
for preapproval compared to those with relatively lesser number of prescriptions 
and subscribers. The reason for this is that with the increase in the number of 
prescriptions there maybe a simultaneous increase in the number of compounded 
prescriptions also. The third party providers who already consider compounded 
prescriptions to be an insignificant part of their prescription volume and are not 
aware of the dollar value do not want to expend time and money on the process 
of preapproval. For those with fewer compounded prescriptions the time and 
money spent on the preapproval process may be neglible. 
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The study of the reimbursement of the compounded prescriptions 
examined several factors related to the reimbursement, review and drug 
utilization review on compounded prescriptions. 
The respondents represented a mix of For Profit Health Insurance 
Companies, Not For Profit Health Insurance Companies, Health Maintenance 
Organization, Mail Service Prescription Companies, Pharmacy Benefit 
Management Companies and Federal/State agencies with varying number of 
subscribers , prescriptions processed and drug benefit models. The respondents 
were selected on a national level and hence the results of this study are 
generalizable to the third party providers throughout U.S. 
The study revealed that the majority of the third party providers do not 
have a preapproved list of compounded prescriptions nor do they require their 
provider to obtain preapproval. In addition most of them cannot identify when 
an FDA approved drug is compounded for unapproved uses and almost half of 
them reimburse for this process. Moreover the third party providers do not 
conduct drug utilization review on compounded prescriptions. Also among those 
who conduct the review perform it only on the single costly ingredient and not 
on all the ingredients. Based on the results of this study, one can conclude that 
currently there appears to be no consistent check by the third party on how the 
prescriptions are compounded by the prescriber or the pharmacist. 
It is clear from this study that there is a need for the third party to 
re evaluate their current coverage, review and reimbursement of compounded 
prescriptions. This study has revealed that there are several areas that need 
additional study. With the introduction of the NCPDP Telecommunication 
Standard Format Version 3.2 it is now relatively easy to conduct concurrent DUR 
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and DUR on all the ingredients. However cost benefit analysis studies need to be 
conducted to evaluate the impact of installing version 3.2 for conducting 
concurrent review, requiring pre approval and conducting DUR on all the 
ingredients . There is also the need to perform studies to determine the extent of 
errors made while compounding the prescriptions. 
Majority of the third party providers currently do not require all pharmacies to 
provide compounding services. The third party can assure that atleast one of their 
participating pharmacy provide the services. Also a provision should be made to 
provide compounding services within a reasonable period of time. 
The rapidly growing segment of the elderly population and the field of 
biotechnology may lead to an increase in the number of prescriptions 
compounded in future. Clearly there is a need for the third parties to reevaluate 
their current coverage, review and reimbursement of compounded prescriptions. 
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. UNIVERSITY OF 
RHODE ISLAND 
APPENDIX Al 
December 12,1994 
Dear Sir or Madam, 
The enclosed survey is an attempt to delermine trurd party coverage 
policy and management of compounded prescriptions. Specific areas such as drug 
utilization review, preapproval and reimbursement scheme are included in this survey. The 
survey is part of my thesis project towards my Master of Sciences in Pharmacy 
Administration. You are assured of anonymity since nowhere in this survey have I 
requested you to identify yourself. I would be very happy if you could return the 
questionnaire by 15th January 1995 in the enclosed self addressed prestamped envelope . 
. Your responses and opinions will be appreciated. If you have any 
questions or su.ggesrionsplease feel free to contact me at 401-792-2789 or write to me. 
Thank you for the time you have spent in completing my questionnaire. 
Sincerely, 
-:Qg~_ 
Renuka Nair 
Graduate Srudent 
cc: A .Taubman, R.Ph.,Ph.D 
Major Professor 
TI"' Unnm1n· of 
l(lfOok h/lmJ U Ofl 
•ffrmw11~ Miort 11"'1 
npMJI opponuni~· -
01\'ISIOJI: OF rHARMACOErlDEMIOLOGY Al'D ADMINISTRATIVE SCIENCES, COLLEGE OF rHAR\.IACY 
Kingston. Rhode Island 02881-0809 
rhon~ : ~01-792-2789 Fax: 401-792-2i81 
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UNIVERSITY OF 
RHODE ISLA.ND 
Dear Sir or Madam, 
APPENDIX A 
January 23, 1995 
The enclosed survey is a follow up of my earlier questionnaire that 
was mailed to you in December 1994. This survey is an attempt to determine third party 
coverage policy and management of compounded prescriptions. Specific areas such as 
drug utilization review, pre approval and reimbursement scheme are included in this 
survey. The survey is part of my thesis project towards my Master of Sciences in 
Pharmacy Administration. If for some reasons you were unable to return the 
earlier queiotionnaire, I would appreciate if you will fill this out and return 
it by 20th February 1995 in the enclosed self addressed pre stamped 
envelope. If you have already mailed the previous questionnaire please do 
not return this again. You are assured of anonymity since nowhere in this survey 
have I requested you to identify yourself. 
Your responses and opinions wil) be appreciated. lf you have any questions or 
suggestions please feel free to cont.act me at 401-792-2789 or write to me_ 
Thank you for the time you have spent in completing my questionnaire. 
cc : A .Taubman. R.Ph. ,Ph.D 
Major Professor 
nt-1.i"i~~ of 
Mo.-klJJ~~­
-tfl,_t"-r-.n•-"" 
,,-1 oppon-irr ""~"· 
COLLEGE OF PHARMACY, DErARnm .. T OF PHAR.\f.ACEUTICS 
Kingston. Rhode hland 02881-0809 
"!'hon<: 4-01 -792-2754 Fax: 40 1-792-2181 
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Graduate Student 
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APPENDIX B 
The following list of questions pertains to reimbursement of compounded 
prescriptions that might be included under your pharmacy benefit programs. 
I request you to kindly fill out the questionnaire and return it in the enclosed self 
addressed envelope. If you have any questions, feel free to contact me at 
401-789-2789. 
Thank you, 
Yours sincerely, 
Renuka Nair 
1. Select the one that best describes your company. 
1. For profit health insurance company 
2. Not for profit health insurance company 
3. Health maintenance organization 
4. Mail service prescription company 
5. Pharmacy benefit management company 
6. Federal/State agency 
2. Total number of prescriptions( compounded & non compounded) processed 
during the calendar year 1993. 
1. 0-50,000 4. 500,000-1,000,000 
2. 50,000-100,000 5. More than 1,000,000 
3. 100,000-500,000 
3. Total number of subscribers (enrolles & dependents) enrolled under the 
drug benefit program during the calendar year 1993. 
1. 0-5,000 5. 100,000-500,000 
2. 5,000-10,000 6. 500,000-l,000,000 
3. 10,000-50,000 7. More than 1,000,000 
4. 50,000-100,000 
4. Do you require the pharmacist to differentiate between non compounded 
and compounded prescriptions for reimbursement? 
1. Yes 2. No 
5. How many drug benefit models do you administer? 
Capitation Fee for service U & C Other 
1. None 
2. One 
3. Two 
4. Three 
5. Four 
6. More than four 
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6. lndicate the type of models that reimburse compounded prescriptions. 
All models Some mcx:iels 
1. None 
2. One 
3. Two 
4. Three 
5. Four 
6. More than four 
7. For those plans that do not presently reimburse compounded 
prescriptions, do you intend reimbursing them in future? 
1. Yes, within the next year 
2. Yes, within the next two years 
3. Yes, after two years 
4. No 
8 . Do you have a preapproved list of prescriptions to be compounded? 
1. Yes 2. No 
9. Are you able to identify when an FDA approved drug is being c 
compounded for unapproved uses? 
1. Yes 2. No 
None 
10. Do you reimburse for FDA approved drugs compounded for unapproved 
uses? 
1. Yes 2. No 
11. Do you require that the provider obtain preapproval before he/ she can 
compound and receive reimbursement? 
1. Yes 2. No (If no, skip to question 15) 
12. Indicate the person responsible for obtaining preapproval from your 
company (CHECK ALL THAT APPLY) 
1. Yes 2. No 
13. Check the process for obtaining preapproval 
(CHECK ALL THAT APPLY) 
1. Prior approval form 4. Approval by fax 
2. Approval via computer 5. Other (SPECIFY) 
3. Approval over computer 
55 
( APPENDIX B 
14. Indicate the number of hours it takes to obtain approval. 
1. Immediately 3. Within 48 hours 
2. Within 24 hours 4. More than 48 hours 
15. Define the formulas (e.g. EAC + Dispensing fee) of the following types 
of reimbursement schemes .. 
1. Fee for service 
2. Capitation 
3. Usual and customary 
4. Other (SPECIFY) 
16. Does the reimbursement scheme vary according to the type of 
prescriptions? (CHECK ALL THAT APPLY) 
1. Yes, they differ according to the dosage form 
2. Yes, they differ based on the time required for compounding 
3. No 
4. Other (SPECIFY) 
17. Do you conduct Drug Utilization Review on compounded prescriptions? 
1. Yes 
2. No (IF NO PLEASE ANSWER 17 A) 
17 A. Do you intend conducting them in future? 
1. Yes, within the next year 
2. Yes, within the next two years 
3. Yes, after two years 
4. No 
18. What kind of Drug Utilization Review do you conduct? 
(CHECK ALL THAT APPLY) 
1. Prospective i.e. conducting review before time of dispensing 
2. Concurrent i.e. conducting review at time of dispensing 
3. Retrospective i.e. conducting review after time of dispensing 
19. Do you conduct Drug l}tilization Review only on the single most costly 
ingredient? 
1. Yes, only on the-costly ingredient 
2. On all the ingredients in the formula 
3. Other (SPECIFY) 
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20. Do you allow more than one active ingredient per compounded 
prescription? 
1. Yes 2. No 
21. Has the number of compounded prescriptions increased over the last two 
years? (Skip to question 23) 
1. Increased by 0-5% 4. Increased by 16-20% 
2. Increased by 6-10% 5. Remained the same 
3. Increased by 11-15% 6. Don't know 
22. Has the number of compounded prescriptions decreased over the last two 
years? 
1. Decreased by 0-5% 4. Decreased by 16-20% 
2. Decreased by 6-10% 5. Remained the same 
3. Decreased by 11-15% 6. Don't know 
23. What percentage of total prescription dollars constitute compounding? 
1. Less than 1 % 4. 6%-10% 
2. 1%-5% 5. More than 10% 
24 . Do you require that all your participating pharmacies compound drugs? 
1. Yes, in all the models 
2. Yes, in some models 
3. No 
25. Do you require that the participating pharmacists provide compounding 
services within a reasonable period of time? 
1. Yes, within 24 hours 
2. Yes, more than 24 hours 
3. No 
Once again if you have any questions or concerns feel free to contact me at 
401-792-2789 or write to me. 
PLEASE RETURN IN TIIE ENCLOSED SELF ADDRESSED 
PRESTAMPED ENVELOPE 
THANK YOU 
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OPTIONS LS=80; 
PROC FORMAT; 
VALUE ABCFMT l='FOR PROFIT HEALTH INSURANCE COMPANY' 
2='NOT FOR PROFIT INSURANCE COMPANY' 
3='HEALTH MAINTENANCE ORGANIZATION' 
4='MAIL SERVICE PRESCRIPTION COMPANY' 
5='PHARMACY BENEFIT MANAGEMENT COMPANY' 
6='FEDERAL/STATE AGENCY'; 
VALUE DEFFMT 1='0-50000' 
2='50000-100000' 
3='100000-500000' 
4='500000-1000000' 
5='MORE THAN 1000000'; 
VALUE GHIFMT 1='0-5000' 
2='5000-10000' 
3='10000-50000' 
4='50000-100000' 
5='100000-500000' 
6='500000-1000000' 
7='MORE THAN 1000000'; 
VALUE JKLFMT l='YES' 
2= 'NO Ii 
VALUE MNO l='NONE' 
2='0NE' 
3='TW0' 
4='THREE' 
5='FOUR' 
6='MORE THAN FOUR Ii 
VALUE MNOX l='NONE' 
2='0NE' 
3='TWO' 
4='THREE' 
5='FOUR' 
6='MORE THAN FOUR Ii 
VALUE MNOY l='NONE' 
2='0NE' 
3='TW0' 
4='THREE' 
5='FOUR' 
6='MORE THAN FOUR Ii 
VALUE MNOZ l='NONE' 
2='0NE' 
3='TWO' 
4='THREE' 
5='FOUR' 
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6='MORE THAN FOUR'; 
VALUE PQRFMT l='ALL' 
2='SOME' 
3= 'NONE I; 
VALUE PQRXFMT l='ALL' 
2='SOME' 
3= 'NONE I; 
VALUE PQRYFMT l='ALL' 
2='SOME' 
3= 'NONE I; 
VALUE PQRZFMT l='ALL' 
2='SOME' 
3= 'NONE I; 
VALUE STUFMT l='YES NEXT YEAR' 
2='YES NEXT 2 YEARS' 
3='YES AFTER 2 YEARS' 
4='NO' 
5='NOT APPLICABLE'; 
VALUE VWXFMT l='YES' 
2= 'NO I; 
VALUE YZFMT l='YES' 
2= I NO I; 
VALUE ABCAFMT l='YES' 
2= 'NO I; 
VALUE DEFAFMT l='YES' 
2= I NO I; 
VALUE GHIAFMT l='PRESCRIBER' 
2='PHARMACIST' 
3='0THER' 
4='NOT APPLICABLE' 
5='EITHER PRES OR PHARM'; 
VALUE JKLAFMT Ol='FORM' 
02='COMPUTER' 
03='PHONE' 
04='FAX' 
05='0THER' 
06='NOT APPLICABLE' 
07='FORM+PHONE+FAX' 
08='FORM+FAX' 
09='PHONE+FAX' 
10='FORM+COMPUTER+PHONE' 
ll='ALL' 
12='FORM+PHONE+FAX' 
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VALUE MNOAFMT l='IMMEDIATELY' 
2='WITHIN 24H' 
3='WITHIN 48H' 
4='MORE THAN 48H' 
5='NOT APPLICABLE'; 
VALUE PQRAFMT l='FEE FOR SERVICE' 
2='CAPITATION' 
3='U $ C' 
4='0THER' 
5='FEE+CAPITATION' 
6='FEE+CAP+UC' 
7='CAP+UC' 
8='FEE+CAP' 
9= I ALL I; 
VALUE STUAFMT l='YES-DOSAGE' 
2='YES-TIME' 
3='NO' 
4='0THER' 
5='0N DOSAGE & TIME'; 
VALUE VWXAFMT l='YES' 
2= I NO I; 
VALUE YZAFMT l='YES NEXT YEAR' 
2='YES IN NEXT 2 YEARS' 
3='YES AFTER 2YRS' 
4='NO' 
5='NOT APPLICABLE' 
6= I DONT KNOW I; 
VALUE ABCBFMT l='PROSPECTIVE' 
2='CONCURRENT' 
3='RETROSPECTIVE' 
4='ALL' 
5='CON+RETRO' 
6='NOT APPLICABLE' 
7='PROS+RETRO' 
8= I PROS+CON I ; 
VALUE ABAFMT l='YES ON COSTLY INGREDIENT' 
2='YES ON ALL' 
3='0THER' 
4='NOT APPLICABLE' 
5='EITHER ON COSTLY OR ALL'; 
VALUE CDAFMT l='YES' 
2= 'NO I; 
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VALUE EFAFMT 1='0-5%' 
2='6-10%' 
3='11-15%' 
4='16-20%' 
5='REMAINED SAME' 
6='DONT KNOW' 
7='NOT APPLICABLE' 
8= I INCREASED I; 
VALUE GHAFMT 1='0-5%' 
2='6-10%' 
3='11-15%' 
4='16-20%' 
5='REMAINED SAME' 
6='DONT KNOW' 
7='NOT APPLICABLE' 
8= I DECREASED I; 
VALUE IJAFMT l='LESS THAN 1%' 
2='1-5%' 
3='6-10%' 
4='MORE THAN 10%' 
5= I DONT KNOW I ; 
VALUE KLAFMT l='YES IN ALL' 
2='YES IN SOME' 
3= I NO I; 
VALUE MNAFMT l='YES IN 24H' 
2='YES MORE THAN 24H' 
3= 'NO I; 
DATA THESIS; 
MISSING M; 
INPUT ABC 1 DEF 2 GHI 3 JKL 4 MNO 5 MNOX 6 MNOY 7 MNOZ 8 
PQR 9 PQRX 10 PQRY 11 PQRZ 12 STU 13 VWX 14 YZ 15 ABCA 16 
DEFA 17 GHIA 18 JKLA 19-20 MNOA 21 PQRA 22 STUA 23 VWXA 24 
YZA 25 ABCB 26 ABA 27 CDA 28 EFA 29 GHA 30 IJA 31 KLA 32 
MNA 33; 
IF ABC=l OR ABC=4 OR ABC=5 THEN ABCD=l; 
ELSE ABCD=O; 
IF 1 LE DEF LE 3 THEN DEFl=l; 
ELSE IF 4 LE DEF LE 5 THEN DEFl=O; 
IF 1 LE GHI LE 4 THEN GHil=l; 
ELSE IF 5 LE GHI LE 7 THEN GHil=O; 
IF PQR EQ 1 THEN PQRl=O; 
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ELSE IF PQR EQ 2 OR 3 THEN PQRl=l; 
IF PQRX EQ 1 THEN PQRXl=O; 
ELSE IF PQRX EQ 2 OR 3 THEN PQRXl =1; 
IF PQRY EQ 1 THEN PQRYl=O; 
ELSE IF PQRY EQ 2 OR 3 THEN PQRYl=l; 
IF PQRZ EQ 1 THEN PQRZ=O; 
ELSE IF PQRZ EQ 2 OR 3 THEN PQRZ=l; 
IF MNO EQ 1 THEN PQRX=.; 
IF MNOX EQ 1 THEN PQR=.; 
IF MNOY EQ 1 THEN PQRY=.; 
IF MNOZ EQ 1 THEN PQRZ=.; 
IF 1 LE STU LE 3 THEN STUl=l; 
ELSE IF STU=4 THEN STUl=O; 
IF STU=S THEN STU=.; 
IF GHIA=4 THEN GHIA=.; 
IF JKLA=6 THEN JKLA=.; 
IF MNOA=S THEN MNOA=.; 
IF 1 LE STUA LE 2 THEN STUAl=O; 
ELSE IF STUA=3 THEN STUAl=l; 
ELSE IF STUA EQ 4 OR 5 THEN STUAl=O; 
IF 1 LE YZA LE 3 THEN YZAl=O; 
ELSE IF YZA EQ 4 THEN YZAl=l; 
ELSE IF YZA=5 THEN YZA=.; 
IF ABA EQ 1 THEN ABAl=O; 
ELSE IF 2 LE ABA LE 3 THEN ABAl=l; 
ELSE IF ABA EQ 4 THEN ABA=.; 
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ELSE IF ABA EQ 5 THEN ABAl=l; 
IF 1 LE EFA LE 4 THEN EFAl=O; 
ELSE IF 5 LE EFA LE 6 THEN EFAl=l; 
ELSE IF EFA=7 THEN EFA=.; 
ELSE IF EFA=8 THEN EFAl=O; 
IF 1 LE GHA LE 6 THEN EFAl=l; 
ELSE IF GHA=7 THEN GHA=.; 
ELSE IF GHA=8 THEN EFAl=O; 
IF IJA EQ 1 THEN IJAl=l; 
ELSE IF 3 LE IJA LE 4 THEN IJAl=O; 
ELSE IF IJA EQ 5 THEN IJAl=.; 
IF 1 LE KLA LE 2 THEN KLAl=O; 
ELSE IF KLA EQ 3 THEN KLAl=l; 
IF 1 LE MNA LE 2 THEN MNAl=O; 
IF ABCB EQ 6 THEN ABCB= . ; 
ELSE IF MNA EQ 3 THEN MNAl=l; 
FORMAT ABC ABCFMT. DEF DEFFMT. GHI GHIFMT. JKL JKLFMT. 
PQR PQRFMT. PQRX PQRXFMT. PQRY PQRYFMT. PQRZ PQRZFMT. 
STU STUFMT. VWX VWXFMT. YZ YZFMT. ABCA ABCAFMT. 
DEFA DEFAFMT. GHIA GHIAFMT. JKLA JKLAFMT. MNOA MNOAFMT. 
PQRA PQRAFMT. STUA STUAFMT. VWXA VWXAFMT. YZA YZAFMT. 
ABCB ABCBFMT. 
ABA ABAFMT. CDA CDAFMT. EFA EFAFMT. GHA GHAFMT. IJA IJAFMT. 
KLA KLAFMT. MNA MNAFMT.; 
LABEL ABC='TYPE OF THIRD PARTY' 
DEF='TOTAL NUMBER OF PRESCRIPTIONS IN 1993' 
GHI='TOTAL NUMBER OF SUBSCRIBERS' 
JKL='DIFFERENTIATE BETWEEN THE TWO' 
MNO='CAPITATION' 
MNOX='FEE FOR SERVICE' 
MNOY='U & C' 
MNOZ='OTHER' 
PQR='FEE FOR SERVICE- MODEL' 
PQRX='CAPITATION MODEL' 
PQRY='U & C MODEL' 
PQRZ='OTHER MODEL' 
STU='INTEND REIMBURSING IN FUTURE' 
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VWX='PREAPPROVED LIST' 
YZ='ABLE TO IDENTIFY UNAPROVED DRUG' 
ABCA='REIMBURSE FDA UNAPPROVED DRUG' 
DEFA='REQUREMENT FOR PREAPROVAL' 
GHIA='PERSON RESPONSIBLE FOR PREAPPROVAL' 
JKLA='PROCESS FOR PREAPPROVAL' 
MNOA='NUMBER OF HOURS FOR PREAPPROVAL' 
PQRA='FORMULA FOR REIMBURSEMENT' 
STUA='VARYING SCHEME' 
VWXA='DUR' 
YZA='INTEND TO CNDUCT DUR IN FUTURE' 
ABCB='TYPE OF DUR' 
ABA='DUR ON INGREDIENTS' 
CDA='NO. OF INGREDIENTS PER COMPOUNDED PRESCRIPTIONS' 
EFA='INCREASE IN COMPOUNDED PRESCRIPTIONS' 
GHA='DECREASE IN COMPOUNDED PRESCRIPTIONS' 
IJA='PERCENTAGE OF TOTAL DOLLARS' 
KLA='REQUIREMENT FOR PHARMACIES' 
MNA='REASONABLE PERIOD FOR COMPOUNDING'; 
CARDS; 
THE DATA HAS BEEN DELETED TO SAVE SPACE 
PROC FORMAT PRINT; 
PROC FREQ; 
TABLES ABC DEF GHI JKL MNO MNOX MNOY MNOZ PQR PQRX PQRY PQRZ 
STU VWX YZ ABCA DEFA GHIA JKLA MNOA STUA VWXA YZA ABCB ABA 
CDA EFA GHA IJA KLA MNA; 
PROC FREQ; 
TABLES(ABCD DEFl GHil IJAl)*JKL/CHISQ; 
PROC FREQ; 
TABLES (ABCD DE Fl GHil IJAl)*VWX/CHISQ; 
PROC FREQ; 
TABLES (ABCD DEFl GHil IJAl)*YZ/CHISQ; 
PROC FREQ; 
TABLES (ABCD DE Fl GHil IJAl)*ABCA/CHISQ; 
PROC FREQ; 
TABLES (ABCD DEFl GHil IJAl)*DEFA/CHISQ; 
PROC FREQ; 
TABLES (ABCD DE Fl GHil IJAl)*STUAl/CHISQ; 
PROC FREQ; 
TABLES (ABCD DE Fl GHil IJAl)*VWXA/CHISQ; 
PROC FREQ; 
TABLES (ABCD DEFl GHil IJAl)*CDA/CHISQ; 
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PROC FREQ; 
f TABLES (ABCD DE Fl GHil IJAl)*EFAl/CHISQ; 
PROC FREQ; 
TABLES (ABCD DEFl GHil IJAl)*KLAl/CHISQ; 
PROC FREQ; 
TABLES (ABCD DE Fl GHil IJAl)*MNAl/CHISQ; 
PROC FREQ; 
TABLES VWX*DEFA; 
PROC FREQ; 
TABLES IJA*DEF; 
PROC FREQ; TABLES MNO*MNOX*MNOY*MNOZ; 
( 
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TYPE OF THIRD PARTY 
Cumulative Cumulative 
ABC Frequency Percent Frequency Percent 
FOR PROFIT HEALT 8 6.2 8 6.2 
NOT FOR PROFIT I 25 19.4 33 25.6 
HEALTH MAINTENAN 15 11. 6 48 37.2 
MAIL SERVICE PRE 6 4 .7 54 41. 9 
PHARMACY BENEFIT 40 31. 0 94 72.9 
FEDERAL/STATE AG 35 27.1 129 100.0 
Frequency Missing 1 
TOTAL NUMBER OF PRESCRIPTIONS PROCESSED IN 1993 
Cumulative Cumulative 
DEF Frequency Percent Frequency Percent 
0-50000 12 9 . 4 12 9 . 4 
50000-100000 4 3.1 16 12.6 
100000-500000 10 7.9 26 20 . 5 
500000-1000000 21 16 . 5 47 37.0 
MORE THAN 100000 80 63.0 127 100.0 
Frequency Missing 3 
TOTAL NUMBER OF SUBSCRIBERS ENROLLED IN 1993 
Cumulative Cumulative 
GHI Frequency Percent Frequency Percent 
0-5000 2 1.6 2 1.6 
5000-10000 2 1.6 4 3.1 
10000-50000 7 5.5 11 8. 6 
50000-100000 15 11. 7 26 20.3 
100000-500000 48 37 . 5 74 57.8 
500000-1000000 25 19.5 99 77.3 
MORE THAN 100000 29 22.7 128 100.0 
Frequency Missing 2 
ABLE TO DIFFERENTIATE BETWEEN COMPOUNDED AND NON COMPOUNDED PRESCRIPTIONS 
JKL 
YES 
NO 
Frequency 
106 
23 
Cumulative Cumulative 
Percent Frequency Percent 
82 . 2 
17.8 
106 
129 
82.2 
100.0 
Frequency Missing = 1 
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MNO 
1 
2 
3 
4 
5 
6 
MNOX 
1 
2 
3 
4 
5 
6 
MNOY 
1 
2 
3 
4 
5 
6 
PQR 
ALL 
SOME 
NONE 
CAPITATION 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
91 72 . 2 91 72 .2 
6 4.8 97 77.0 
11 8.7 108 85.7 
1 0.8 109 86.5 
3 2.4 112 88.9 
14 11.1 126 100.0 
Frequency Missing = 4 
FEE FOR SERVICE 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
18 14.3 18 14.3 
29 23.0 47 37 . 3 
10 7.9 57 45.2 
4 3.2 61 48.4 
5 4.0 66 52.4 
60 47.6 126 100.0 
Frequency Missing 4 
u & c 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
59 46.8 59 46.8 
17 13.5 76 60.3 
12 9 . 5 88 69.8 
2 1. 6 90 71.4 
2 1. 6 92 73.0 
34 27.0 126 100.0 
Frequency Missing 4 
REIMBURSE FEE FOR SERVICE- MODEL 
Cumulative Cumulative 
Frequency 
102 
6 
1 
Percent 
93.6 
5.5 
0.9 
Frequency 
102 
108 
109 
Frequency Missing 21 
67 
Percent 
93 . 6 
99.1 
100.0 
( 
PQRX 
ALL 
SOME 
NONE 
PQRY 
ALL 
SOME 
NONE 
REIMBURSE CAPITATION MODEL 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
31 
5 
1 
83.8 
1 3 . 5 
2.7 
31 
36 
37 
Frequency Mi ss ing 93 
REIMBURSE U & C MODEL 
83.8 
97 . 3 
100.0 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
STU 
59 
6 
4 
85 . 5 
8 . 7 
5.8 
59 
65 
69 
85.5 
94 . 2 
100.0 
Frequency Missing 61 
INTEND REIMBURSING IN FUTURE 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
YES NEXT YEAR 
NO 
2 
4 
33.3 
66.7 
2 
6 
33.3 
100 . 0 
vwx 
YES 
NO 
YZ 
YES 
NO 
Frequency Missing = 124 
Frequency 
14 
116 
PREAPPROVED LIST 
Cumulative Cumulative 
Percent Frequency Percent 
10.8 
89.2 
14 
130 
10.8 
100 . 0 
ABLE TO IDENTIFY UNAPROVED DRUG 
Frequency 
41 
89 
Percent 
68 
31. 5 
68 . 5 
Cumulative Cumulative 
Frequency 
41 
130 
Percent 
31.5 
100 . 0 
( 
( 
REIMBURSE FDA UNAPPROVED DRUG USES 
Cumulative Cumulative 
ABCA Frequency Percent Frequency Percent 
YES 
NO 
64 
63 
50 .4 
49.6 
64 
127 
Frequency Missing 3 
REQUREMENT FOR PREAPROVAL 
50.4 
100.0 
Cumulative cumulative 
DEFA Frequency Percent Frequency Percent 
YES 
NO 
23 
106 
17.8 
82.2 
23 
129 
Frequency Missing 1 
17.8 
100.0 
PERSON RESPONSIBLE FOR PREAPPROVAL 
GHIA 
PRESCRIBER 
PHARMACIST 
EITHER PRES OR P 
JKLA 
FORM 
COMPUTER 
PHONE 
FORM+ PHONE+ FAX 
FORM+FAX 
PHONE+ FAX 
FORM+COMPUTER+PH 
ALL 
PHONE+FAX+COMPUT 
COMPUTER+PHONE 
Frequency 
5 
11 
7 
Cumulative Cumulative 
Percent Frequency Percent 
21. 7 
47.8 
30.4 
5 
16 
23 
21. 7 
69.6 
100.0 
Frequency Missing = 107 
PROCESS FOR PREAPPROVAL 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
2 8 . 7 2 8.7 
1 4.3 3 13 .0 
7 30.4 10 43.5 
4 17.4 14 60.9 
1 4.3 15 65.2 
1 4.3 16 69.6 
3 13.0 19 82.6 
2 8.7 21 91.3 
1 4 . 3 22 95.7 
1 4.3 23 100.0 
Frequency Missing = 107 
69 
NUMBER OF HOURS FOR PREAPPROVAL 
MNOA 
IMMEDIATELY 
WITHIN 24H 
WITHIN 48H 
Frequency 
10 
8 
5 
Cumulative Cumulative 
Percent Frequency Percent 
43.5 
34.8 
21 . 7 
10 
18 
23 
43 . 5 
78 . 3 
100.0 
Frequency Missing 107 
FACTORS AFFECTING THE REIMBURSEMENT SCHEME 
Cumulative Cumulative 
STUA Frequency Percent Frequency Percent 
YES-DOSAGE 5 4.0 5 4.0 
YES - TIME 10 8.0 15 12.0 
NO 97 77.6 112 89.6 
OTHER 6 4 . 8 118 94.4 
ON DOSAGE & TIME 7 5.6 125 100.0 
Frequency Missing 5 
DUR 
Cumulative Cumulative 
VWXA Frequency Percent Frequency Percent 
YES 
YES 
YES 
NO 
YES 
NO 
YZA 
NEXT YEAR 
IN NEXT 2 YR 
AFTER 2YRS 
DONT KNOW 
74 
55 
57.4 
42.6 
74 
129 
Frequency Missing 1 
INTEND TO CNDUCT DUR IN FUTURE 
57.4 
100.0 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
14 25.0 14 25.0 
5 8.9 19 33.9 
2 3.6 21 37.5 
32 57.1 53 94.6 
3 5.4 56 100.0 
Frequency Missing 74 
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ABCB 
PROSPECTIVE 
CONCURRENT 
RETROSPECTIVE 
ALL 
CON+RETRO 
PROS+RETRO 
PROS+CON 
ABA 
YES ON COSTLY IN 
YES ON ALL 
EITHER ON COSTLY 
TY PE OF DUR 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
4 5 . 5 4 5.5 
7 9.6 11 15.1 
22 30 . 1 33 4 5. 2 
19 26.0 52 71. 2 
14 19 . 2 66 90.4 
6 8 . 2 72 98.6 
1 1. 4 73 100.0 
Frequency Missing 57 
DUR ON INGREDIENTS 
Frequency 
30 
38 
5 
Percent 
41.1 
52.1 
6 . 8 
Cumulative Cumulative 
Frequency 
30 
68 
75 
Percent 
41.1 
93.2 
100.0 
Frequency Missing 57 
ALLOW MORE THAN 1 ACTIVE INGREDIENT PER COMPOUNDED PRESCRIPTION 
0-5% 
6-10% 
CDA 
YES 
NO 
11-15% 
16-20% 
REMAINED 
DONT KNOW 
INCREASED 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
121 
7 
94.5 
5.5 
121 
128 
Frequency Missing = 2 
94.5 
100.0 
INCREASE IN COMPOUNDED PRESCRIPTIONS 
Cumulative Cumulative 
EFA Frequency Percent Frequency Percent 
19 15 . 7 19 15 . 7 
10 8.3 29 24.0 
5 4.1 34 28.1 
2 1. 7 36 29 . 8 
SAME 22 18 . 2 58 47.9 
61 50.4 119 98 . 3 
2 1.7 121 100.0 
Frequency Missing 9 
71 
( 
DECREASE IN COMPOUNDED PRESCRIPTIONS 
Cumulative Cumulative 
GHA Frequency Percent Frequency Percent 
0-5% 6 6.6 6 6 . 6 
6-10% 1 1.1 7 7.7 
16-20% 2 2.2 9 9.9 
REMAINED SAME 21 23.1 30 33.0 
DONT KNOW 61 67 . 0 91 100.0 
Frequency Missing 39 
PERCENTAGE OF COMPOUNDED PRESCRIPTIONS IN TERMS OF TOTAL DOLLAR SALES 
Cumulative Cumulative 
IJA Frequency Percent Frequency Percent 
LESS THAN 1% 83 66.4 83 66.4 
1-5% 30 24.0 113 90 . 4 
6-10% 2 1. 6 115 92.0 
DONT KNOW 10 8.0 125 100.0 
Frequency Missing 5 
REQUIREMENT PHARMACIES TO COMPOUND PRESCRIPTIONS 
KLA 
YES IN ALL 
YES IN SOME 
NO 
Frequency 
45 
2 
83 
Percent 
34 . 6 
1.5 
63 . 8 
Cumulative Cumulative 
Frequency 
45 
47 
130 
Percent 
34.6 
36 . 2 
100.0 
REQUIRE PHARMACIES TO COMPOUND WITHIN REASONABLE TIME PERIOD 
MNA 
YES IN 24H 
YES MORE THAN 24 
NO 
Frequency 
72 
28 
5 
97 
Percent 
21 . 5 
3 . 8 
74.6 
Cumulative 
Frequency 
28 
33 
130 
Cumulative 
Percent 
21 . 5 
25.4 
100.0 
( 
( 
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